Showing results (111-120 of 155) with videos related to

Sort By:
Pageof 16
Clinical Chemistry and Laboratory Medicine|May 9, 2007
Validation of a reverse-hybridization StripAssay for the simultaneous analysis of common alpha-thalassemia point mutations and deletionsHelene Puehringer, Hossein Najmabadi, Hai-Yang Law, et al.
British Journal of Haematology|September 13, 2014
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemiaAli T Taher, John B Porter, Vip Viprakasit, et al.
Blood Cells, Molecules & Diseases|August 15, 2017
Prevalence and predictors of cardiac and liver iron overload in patients with thalassemia: A multicenter study based on real-world dataRungroj Krittayaphong, Vip Viprakasit, Pairash Saiviroonporn, et al.
Clinical and Translational Science|September 18, 2025
Bridging Pharmacokinetics and Pharmacodynamics: A PBPK/PD Model-Based Approach for Deferasirox Dosing in Transfusion-Dependent ThalassemiaWatchara Sakares, Udomsak Udomnilobol, Xian Pan, et al.
Blood|May 17, 2012
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled studyAli T Taher, John Porter, Vip Viprakasit, et al.
The Lancet. Haematology|January 2, 2026
Management of transfusion-dependent β-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resourcesKhaled M Musallam, Sujit Sheth, Maria Domenica Cappellini, et al.
Blood Cells, Molecules & Diseases|February 9, 2016
Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS studyAli T Taher, M Domenica Cappellini, Yesim Aydinok, et al.
American Journal of Hematology|April 5, 2013
Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patientsAli T Taher, John B Porter, Vip Viprakasit, et al.
Blood|May 3, 2015
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overloadYesim Aydinok, Antonis Kattamis, M Domenica Cappellini, et al.
Blood|February 5, 2005
In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutationsLisa M Schimanski, Hal Drakesmith, Alison T Merryweather-Clarke, et al.
Pageof 16